PKN605

DRUG3 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Atrial FibrillationParticipants With Moderate and Severe Renal Impairment and Healthy Participants

Phase 1

A Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Subjects With Normal Renal Function

Not yet recruitingNCT07797322

Novartis PharmaceuticalsParticipants With Moderate and Severe Renal Impairment and Healthy Participants

Start: 2026-09-01End: 2027-02-18Target: 40Updated: 2026-09-01

Phase 2

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

RecruitingNCT07217067

Novartis PharmaceuticalsAtrial Fibrillation

Start: 2025-10-28End: 2027-09-09Target: 165Updated: 2026-07-31

A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation

RecruitingCTIS2025-520518-79-00

Novartis Pharma AGAtrial Fibrillation

Start: 2026-01-06Target: 41Updated: 2025-11-28